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52 %). Also, PFS and OS after start of chemotherapy were 
comparable between both patient groups (hazard ratio 
0.91; 95 % confidence interval 0.63–1.30 and 1.03; 95 % 
CI 0.71–1.49, respectively). Thirty-six CHEK2 and 32 
non-CHEK2 patients received first-line endocrine therapy 
(mainly tamoxifen) for MBC. No significant differences 
were observed in objective response rate to, and PFS and 
OS after start of endocrine therapy.
Conclusion No differential efficacy of chemotherapy and 
endocrine therapy given for MBC was observed in CHEK2 
versus non-CHEK2 patients.
Keywords Metastatic breast cancer · CHEK2 1100delC · 
Chemotherapy · Endocrine therapy · Response · Survival
Introduction
CHEK2 is a tumor suppressor gene associated with a 
moderately increased cumulative lifetime breast cancer 
(BC) risk (1.4- to 3-fold; Cybulski et al. 2011; Meijers-
Heijboer et al. 2002; Weischer et al. 2008). The CHEK2 
gene encodes for the protein kinase CHEK2 which plays a 
critical role in cell cycle control and DNA damage repair. 
In response to double-strand DNA breaks, CHEK2 is 
activated by ataxia telangiectasia mutated (ATM) and is 
involved in cell cycle control, DNA repair and apoptosis. 
CHEK2 kinase phosphorylates TP53 and BRCA1, where-
upon BRCA1 represses the non-homologous end-joining 
pathway and activates the homologous recombination 
repair pathway (Nevanlinna and Bartek 2006; Roeb et al. 
2012; Tung and Silver 2011). Different CHEK2 variants 
have been described, and in the Netherlands, the prevalence 
of the CHEK2 1100delC variant is relatively high, while 
other CHEK2 variants (IVS2 + 1G > A, del5395, 1157T) 
Abstract 
Purpose The role of CHEK2 in DNA repair by homolo-
gous recombination suggests that CHEK2-associated breast 
cancer (BC) patients might be more sensitive to chemother-
apy inducing double-strand DNA breaks, but results hereon 
are lacking. We compared the sensitivity to first-line chem-
otherapy and endocrine therapy between CHEK2 1100delC 
and non-CHEK2 metastatic breast cancer (MBC) patients.
Methods Sixty-two CHEK2 1100delC MBC patients 
were selected from three cohorts genotyped for CHEK2 
1100delC (one non-BRCA1/2 cohort and two sporadic 
cohorts). Controls were 62 non-CHEK2 MBC patients, 
matched for age at and year of primary BC diagnosis, and 
year of metastatic disease. Objective response rate (com-
plete and partial response) to, and progression-free sur-
vival (PFS) and overall survival (OS) after start of first-
line chemotherapy and endocrine therapy were compared 
between CHEK2 and non-CHEK2 patients.
Results Median age at BC diagnosis was 46 and 51 years 
at MBC diagnosis. First-line chemotherapy consisted 
of anthracycline-based chemotherapy (n = 73), taxanes 
(n = 16), CMF(-like) chemotherapy (n = 33) and taxane/
anthracycline regimens (n = 2). CHEK2 and non-CHEK2 
patients had a comparable objective response rate (44 vs. 
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are very rare (The CHEK2 Breast Cancer Case Control 
Consortium 2004; Hollestelle et al. 2010; Meijers-Heijboer 
et al. 2002).
BC patients carrying the germline CHEK2 1100delC 
mutation mainly develop estrogen receptor (ER)-positive 
BC (de Bock et al. 2006; Nagel et al. 2012; Weischer et al. 
2012) and have an twofold to threefold increased risk of 
developing contralateral BC. Moreover, a worse distant 
disease-free survival and overall survival (OS) for CHEK2 
1100delC BC patients have been reported (de Bock et al. 
2004; Kriege et al. 2014; Schmidt et al. 2007; Weischer et al. 
2012). A plausible explanation for the worse survival might 
be a decreased sensitivity to (adjuvant) systemic therapy in 
CHEK2 compared to non-CHEK2 BC patients. On the other 
hand, the function of the CHEK2 protein kinase in the repair 
of double-strand DNA breaks suggests that BC patients car-
rying a CHEK2 mutation might have an increased sensitiv-
ity to chemotherapeutic agents causing double-strand DNA 
breaks, such as platinum, alkylating agents and/or anthra-
cyclines (Nevanlinna and Bartek 2006). However, data on 
the efficacy of systemic therapy in CHEK2-associated BC 
patients are very limited so far. In a previous study of our 
group regarding distant disease-free survival and breast can-
cer-specific survival of primary BC, no differential effect of 
adjuvant chemotherapy or endocrine therapy was observed 
in CHEK2 1100delC compared with non-CHEK2 breast can-
cer patients (Kriege et al. 2014).
To further elucidate the potentially differential efficacy of 
systemic therapy among CHEK2 mutation carriers compared 
to non-CHEK2 patients, we assessed the efficacy of stand-
ard first-line chemotherapy given for metastatic breast cancer 
(MBC) in CHEK2 1100delC compared with non-CHEK2 
patients. Furthermore, the efficacy of first-line endocrine 
therapy for MBC was also determined in both groups.
Patients and methods
For the current study, we used a database available from a 
previous study (Kriege et al. 2014), consisting of women 
with invasive BC genotyped for CHEK2 1100delC from 
three different cohorts. One cohort consisted of non-
BRCA1/2 patients from the Rotterdam Family Cancer 
Clinic (non-BRCA1/2 cohort). The two other cohorts con-
sisted of sporadic BC patients from (1) the ORIGO study, 
a study designed to investigate the prevalence of BRCA1/2 
mutations in an unselected BC population (ORIGO cohort) 
and (2) the Rotterdam Medical Oncology Tumor Bank 
database (RMOT cohort). More details regarding these 
cohorts have previously been described (Kriege et al. 
2014). The inclusion criteria for the previous study were 
first BC diagnosed before age 80 and after 1970, and fol-
low-up data available. Patients with a proven BRCA1 or 
BRCA2 mutation were excluded. For the current study, BC 
patients with a CHEK2 1100delC mutation and treated with 
first-line chemotherapy (irrespective of type) for metastatic 
disease were selected from the database.
The CHEK2 1100delC mutation status of the respective 
BC patients in the three cohorts was determined by either 
allele-specific oligonucleotide hybridization or Taqman 
genotyping as described earlier. DNA was isolated from 
peripheral blood of patients from the non-BRCA1/2 and 
ORIGO cohorts and from freshly frozen tumor tissue of 
patients from the RMOT cohort as described (Kriege et al. 
2014). In this paper, we refer to CHEK2 1100delC muta-
tion carriers as CHEK2 mutation carriers.
In total, 4854 patients were tested for CHEK2 1100delC. 
From this cohort, 199 (4.1 %) had a CHEK2 1100delC 
mutation of whom 90 (45.2 %) patients developed distant 
metastases (Fig. 1). From the 90 CHEK2 1100delC BC 
patients with distant metastases, 28 patients were excluded 
because they were not treated with chemotherapy for MBC 
(n = 22) or because information on treatment for MBC 
was incomplete (n = 6). The eventually 62 eligible CHEK2 
mutation carriers with MBC were matched (1:1) for age at 
and period of primary BC diagnosis (within 5 years) and 
year of diagnosis of metastatic disease (within 5 years) 
with non-CHEK2 patients treated with chemotherapy for 
MBC, selected from the same database.
This study was approved by the Medical Ethical Com-
mittee of the Erasmus MC, Rotterdam, the Netherlands 
(MEC 2009-344).
Data collection
For all CHEK2 and non-CHEK2 MBC patients included 
in the current study (n = 124), data were extracted from 
hospital charts concerning patient and tumor characteris-
tics, (systemic) treatment for primary BC, and if applica-
ble for contralateral BC and loco–regional recurrence, date 
and location of distant metastases, type of and response to 
treatment for metastatic disease, date of progressive dis-
ease during or after first-line therapy (chemotherapy and/
or endocrine therapy) for MBC and death. End date of the 
study was date of death, date of last medical contact or date 
of end of study (1-6-2013), whichever came first.
Endpoints
The endpoints in this study were objective response rate 
and clinical benefit rate to, and progression-free survival 
(PFS) and OS after start of first-line chemotherapy and 
first-line endocrine therapy for MBC. Objective response 
was defined as complete response (CR) or partial response 
(PR), and clinical benefit as objective response or sta-
ble disease >6 months, according to International Union 
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Against Cancer Criteria (Hayward et al. 1977), as a large 
part of the patient was treated before the introduction of 
the RECIST criteria in 2000. PFS after first-line systemic 
therapy (chemotherapy or endocrine therapy) was defined 
as time between start of either chemotherapy or endocrine 
therapy and date of progressive disease. OS after first-line 
systemic therapy (chemotherapy or endocrine therapy) was 
defined as time between start of either chemotherapy or 
endocrine therapy and death due to any reason [one patient 
(with a CHEK2 mutation) died from another reason than 
breast cancer (heart disease)].
For the study aims regarding the efficacy of first-line 
chemotherapy, all patients who received chemotherapy for 
MBC were included, irrespective of whether they also were 
treated with endocrine therapy for MBC before chemother-
apy. Patients who were treated with an anthracycline-based 
regimen (without taxanes) as first-line chemotherapy were 
analyzed separately. For the analyses regarding the efficacy 
of endocrine therapy for MBC, we only included patients 
receiving endocrine therapy before chemotherapy (n = 68; 
36 CHEK2 and 32 non-CHEK2 patients), because endo-
crine therapy after chemotherapy was most times given as 
consolidation therapy.
Statistical analyses
Differences in patient, tumor and treatment characteristics 
between CHEK2 and non-CHEK2 patients were tested by 
a Chi-square test or Fisher’s exact test for categorical vari-
ables or by a t test for continuous variables. Differences 
in response rate to first-line chemotherapy and to first-line 
endocrine therapy between the patient groups were tested 
by a Chi-square test with linear by linear association. The 
Kaplan–Meier method was used to calculate PFS and OS 
after start of first-line chemotherapy and first-line endo-
crine therapy. Censoring events were date of last medical 
contact or end date of the study. Differences in PFS and OS 
between CHEK2 and non-CHEK2 patients were tested by 
a log-rank test. The Cox proportional hazard method was 
used to calculate univariate and multivariate hazard ratios 
(HR) and 95 % confidence intervals (CI) for the risk of 
progression and death after start of first-line chemotherapy 
and after start of first-line endocrine therapy for MBC in 
CHEK2 versus non-CHEK2 patients. Potential confound-
ers included in the multivariate model were as follows: 
age at diagnosis (<50; ≥50), ER status (negative; positive; 
unknown), adjuvant chemotherapy (yes; no), metachronous 
contralateral BC (yes; no), type of first distant metastases 
(soft tissue; bone; visceral) and distant disease-free interval 
(<2 years; ≥2 years) and for the models regarding chemo-
therapy also endocrine therapy for MBC before chemother-
apy (yes; no) and time between first distant metastasis and 
start of first-line chemotherapy (continuous).
Two-sided P values <0.05 were considered statistically 
significant. All analyses were performed with the use of 
SPSS software (version 21.0).
Fig. 1  Flowchart for patient 
selection
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Results
Patient, tumor and treatment characteristics
Patient, tumor and adjuvant treatment characteristics 
of CHEK2 1100delC and non-CHEK2 BC patients are 
depicted in Table 1. The median age at primary BC diag-
nosis was 45.4 years for the CHEK2 mutation carriers and 
46.7 years for the non-CHEK2 patients, while the median 
age at the diagnosis of first distant metastases was 51.0 
and 52.2 years, respectively. No significant differences in 
these tumor characteristics were observed between CHEK2 
mutation carriers and non-CHEK2 patients. Tumors were 
mainly ER positive in both groups (89 and 75 % in CHEK2 
and non-CHEK2 BC patients, respectively). Data regarding 
human epidermal growth factor receptor 2 (HER2) status 
are not mentioned, as these were mostly missing. First dis-
tant metastases occurred in bone for 47 % of the mutation 
carriers and 44 % of the non-CHEK2 patients, respectively, 
and in viscera for 50 and 48 % of the patients, respectively.
First‑line chemotherapy
Type of and response to first-line chemotherapy for MBC 
are shown in Table 2. First-line chemotherapy for MBC 
mainly consisted of anthracycline-based chemotherapy, 
being given to 34 (55 %) CHEK2 and 39 (63 %) non-
CHEK2 patients, of whom 11 patients (six CHEK2 and 
five non-CHEK2) continued with CMF after the maximal 
cumulative anthracycline dose (data not shown). The num-
ber of patients receiving endocrine therapy after first-line 
chemotherapy (as consolidation therapy) was comparable 
for the CHEK2 mutation carriers (n = 18; 29 %) and the 
non-CHEK2 patients (n = 16; 26 %).
The objective response rate to first-line chemotherapy 
was similar for CHEK2 and non-CHEK2 patients (42 and 
44 %, respectively), and the clinical benefit rate was also 
similar in both groups (77 %). In the subgroup analysis of 
patients receiving an anthracycline-based regimen as first-
line chemotherapy for MBC, no significant differences in 
objective response rate (52 and 43 %, respectively) and 
Table 1  Patient, tumor and adjuvant treatment characteristics
CHEK2 Non-CHEK2 P
N % N %
Number of patients 62 62
Median age at diagnosis 
(years)
45.4 46.7 0.76
Range 25.5–67.1 24.0–67.5
Median age at diagnosis M1 
(years)
51.0 52.2 0.69
Range 30.0–69.2 27.7–68.7
Year of diagnosis M1
 <1990 8 13 7 11 0.43
 1990–2000 30 48 26 42
 ≥2000 24 39 29 47
Tumor size
 T1 24 41 13 22 0.05
 T2 26 44 32 56
 T3, T4 9 15 13 22
 Unknown 3 4
Node positive 35 57 40 67 0.29
Not done/unknown 1 2
M1 at diagnosis 3 5 2 3 1.00
Histologic grade
 I 8 18 5 10 0.33
 II 13 29 15 30
 III 24 53 30 60
 Unknown 17 12
Estrogen receptor positive 54 89 46 75 0.06
Unknown 1 1
Progesterone receptor  
positive
42 79 36 67 0.14
Adjuvant chemotherapy*
 No 32 54 29 48 0.81
 Anthracyclines 17 29 19 32
 Other 10 17 12 20
 Not applicable (M1) 3 2
Adjuvant endocrine therapya
 No 40 69 38 63 0.56
 Yes 18 31 22 37
 Not applicable (M1) or 
unknown
4 2
Contralateral breast cancer
 Yes 12 19 5 8 0.07
 No 50 81 57 92
Distant disease-free interval
 ≤1 year 7 11 6 10 0.93
 1–2 years 11 18 13 21
 2–5 years 21 34 21 34
 >5 years 23 37 22 35
Site of first distant metastasisb
 Soft tissue 2 3 5 8 0.50
Table 1  continued
CHEK2 Non-CHEK2 P
N % N %
 Bone 29 47 27 44
 Visceral 31 50 30 48
a Including chemotherapy or endocrine therapy for a second breast 
cancer or for a loco–regional recurrence
b In case of multiple sites, the site with the worst prognosis was cho-
sen (visceral > bone > soft tissue)
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clinical benefit rate (74 and 69 %, respectively) were observed 
between CHEK2 mutation carriers and non-CHEK2 patients.
PFS and OS after start of first‑line chemotherapy
Data on PFS and OS after start of first-line chemotherapy 
for MBC are shown in Table 3 and Fig. 2. CHEK2 and 
non-CHEK2 BC patients had a comparable 12-month PFS 
(28 vs. 32 %) and 12-month OS (64 vs. 76 %). Also, after 
adjusting for possible confounding factors (see method sec-
tion), no significant differences in PFS (HR 0.91; 95 % CI 
0.63–1.30) and OS (HR 1.03; 95 % CI 0.71–1.49) were 
observed between the CHEK2 and non-CHEK2 groups. As 
PFS after start of first-line chemotherapy could have been 
influenced by consolidation endocrine therapy, we also per-
formed the analyses for PFS, with censoring at date of start 
of consolidation endocrine therapy in respective patients. 
In these additional analyses, we observed no significantly 
different PFS between CHEK2 1100delC mutation carri-
ers and non-CHEK2 patients (HR 0.92; 95 % CI 0.63–1.52; 
data not shown).
Further, regarding the analyses for PFS for patients 
treated with anthracycline-based chemotherapy, no signifi-
cant differences were observed between CHEK2 and non-
CHEK2 BC patients (at 12 months 29 vs. 36 %, respec-
tively; multivariate HR 0.92; 95 % CI 0.57–1.48).
First‑line endocrine therapy
Response to first-line endocrine therapy for MBC was 
evaluated in 36 CHEK2 1100delC and 32 non-CHEK2 
patients (Table 4). The objective response rate was 14 % in 
Table 2  First-line 
chemotherapy for metastatic 
breast cancer
CMF cyclophosphamide, methotrexate and fluorouracil
a Anthracycline-based chemotherapy consisted of the following regimens: 19 × FAC, 14 × FEC, 3 × AC 
in the CHEK2 group (for three cases, the specific regimen was unknown) and 23 × FAC, 7 × FEC and 
4 × AC in the non-CHEK2 group (FAC fluorouracil, adriamycin, cyclophosphamide, FEC fluorouracil, epi-
rubicin, cyclophosphamide and AC adriamycin, cyclophosphamide)
b Taxanes were given 2× in combination with trastuzumab in the CHEK2 group; and 3× in combination 
with trastuzumab, 1× in combination with bevacizumab, 1× in combination with trastuzumab and bevaci-
zumab, 2× in combination with methotrexate in the non-CHEK2 group
c Anthracycline/taxane regimen consisted of adriamycin and docetaxel in the CHEK2 patient and of FAC 
followed by docetaxel in the non-CHEK2 patient
CHEK2 Non-CHEK2 P
N % N %
Type of chemotherapy
 Anthracycline baseda 34 55 39 63 0.25
 Taxane basedb 6 10 10 16
 Anthracycline/taxane regimenc 1 2 1 2
 CMF/CMF-like 21 34 12 19
Best response
 Objective response 27 44 32 52 0.71
 Stable disease 21 35 18 29
 Progressive disease 13 21 12 19
 Unknown 1
 Clinical benefit (objective response and stable disease >6 months) 47 77 48 77 0.96
Progressive disease
 During chemotherapy 26 42 27 44 0.92
 After chemotherapy
 No consolidation endocrine therapy 18 29 19 31
 Consolidation endocrine therapy 18 29 16 26
Anthracycline-based therapy
 Number of patients 34 39
Best response
 Objective response 18 52 17 43 0.70
 Stable disease 8 24 12 31
 Progressive disease 8 24 10 26
 Clinical benefit (objective response and stable disease >6 months) 25 74 27 69 0.69
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CHEK2 mutation carriers and 19 % in non-CHEK2 patients 
(P = 0.82). Also PFS (HR 1.50; 95 % CI 0.90–2.49) and 
OS (multivariate HR 1.51; 95 % CI 0.89–2.57) after start of 
first-line endocrine therapy were both not significantly dif-
ferent between CHEK2 and non-CHEK2 BC patients.
Discussion
Currently, only a few biomarkers are used for therapy 
stratification in BC patients (e.g., ER, HER2), whereas 
biomarkers predictive of treatment response will contrib-
ute to further tailoring and improving BC treatment, i.e., 
avoiding toxic therapy for those not benefiting of it. Muta-
tions in BC risk genes might be valuable markers for ther-
apy response prediction, which already has been reported 
for BRCA1- and BRCA2-associated BC, suggesting higher 
sensitivity to anthracyclines, platinum and potentially 
other agents (Bayraktar and Gluck 2012; Kriege et al. 
2009; Tutt et al. 2010).
The current study is the first to address the response to 
systemic therapy in CHEK2 1100delC MBC patients. We 
observed a similar efficacy of first-line chemotherapy given for 
Table 3  Progression-free and overall survival after first-line chemo-
therapy
a Adjusted for distant disease-free interval
b None of the variables (age at diagnosis, ER status, adjuvant chemo-
therapy, metachronous contralateral breast cancer, type of first metas-
tases, distant disease-free interval, endocrine therapy for metastatic 
disease before chemotherapy, time between first distant metastasis 
and start chemotherapy) had >10 % influence
CHEK2 Non-
CHEK2
P
N % N %
Progression-free survival
All chemotherapy 0.84
6 months 41 66 42 68
12 months 17 28 19 32
24 months 5 8 2 3
HR univariate (95 % CI) 0.96 (0.67–1.38)
HR multivariate (95 % CI)a 0.91 (0.63–1.30)
Anthracycline-based  
chemotherapy
0.92
6 months 22 65 24 62
12 months 10 29 13 36
24 months 2 6 1 3
HR univariate (95 % CI) 0.98 (0.61–1.56)
HR multivariate (95 % CI)a 0.92 (0.57–1.48)
Overall survival 0.89
6 months 56 90 57 92
12 months 39 64 46 76
24 months 28 49 31 51
36 months 14 24 14 28
HR univariate (95 % CI)b 1.03 (0.71–1.49)
Fig. 2  Progression-free survival (PFS) in all metastatic breast can-
cer patients (a) and in metastatic breast cancer patients treated with 
anthracycline-based chemotherapy (b) and overall survival (OS) in 
metastatic breast cancer patients (c)
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MBC in CHEK2 1100delC mutation carriers compared to non-
CHEK2 patients. Both response rate to, and PFS and OS after 
start of first-line chemotherapy were similar in patients with 
and without the CHEK2 1100delC mutation. Also, in patients 
treated with anthracycline-based chemotherapy, no differential 
efficacy was observed between CHEK2 1100delC-associated 
and non-CHEK2 patients. These observations are in line with 
our previous findings concerning no differential effect of adju-
vant chemotherapy on distant disease-free and breast cancer-
specific survival in CHEK2 1100delC mutation carriers versus 
non-CHEK2 patients with early BC (Kriege et al. 2014).
An explanation for the lack of improved efficacy of 
anthracycline-based chemotherapy in CHEK2 mutation 
carriers compared with non-CHEK2 patients, as observed 
in the current study, might be that a proportion of the 
BCs diagnosed in CHEK2 1100delC mutation carriers are 
not driven by the loss of CHEK2 function, but still carry 
a wild-type CHEK2 allele (either with or without loss of 
the mutant allele). Finally, the results might be due to the 
relatively small numbers (34 CHEK2 and 39 non-CHEK2 
patients treated with anthracyclines).
Our observation regarding no differential efficacy of 
first-line endocrine therapy for MBC between CHEK2 
1100delC and non-CHEK2 patients is in line with the 
results of our previous study regarding no differential 
effect of adjuvant endocrine therapy on distant disease-free 
and BCSS in CHEK2 and non-CHEK2 early BC patients 
(Kriege et al. 2014). To our knowledge, there are no other 
reports on the efficacy of endocrine therapy in CHEK2 BC 
patients yet. In our opinion, however, the question is very 
relevant as the majority of CHEK2 BCs is hormone sensi-
tive at diagnosis (de Bock et al. 2004; Kriege et al. 2014; 
Schmidt et al. 2007; Weischer et al. 2012) and DNA diag-
nostics for CHEK2 have recently been implemented in 
the Netherlands (as part of genetic testing in the context 
of familial BC) and will be possibly impemented in other 
countries with a high prevalence. Although we included 
compared to other series a relative large number of CHEK2 
metastatic breast cancer patients, the number of CHEK2 
patients treated with endocrine therapy for MBC was small 
(n = 36), and future studies with larger sample sizes are 
needed to address this question further.
Results from the current study in MBC patients and 
our previous study in early BC patients regarding efficacy 
of chemotherapy and endocrine therapy do not explain 
the worse prognosis that has been reported for CHEK2 
1100delC-associated compared with BC patients with-
out this mutation (de Bock et al. 2004; Kriege et al. 2014; 
Schmidt et al. 2007; Weischer et al. 2012). Of note, this 
worse prognosis was not observed in all studies pub-
lished in CHEK2 mutation carriers to date. A recent paper 
by Huzarski et al. (Huzarski et al. 2014) did not observe 
a worse survival in 487 CHEK2 mutation carriers from 
Poland; however, in this patient group, the majority of the 
patients had not the 1100delC, but another CHEK2 vari-
ant (Huzarski et al. 2014). Whether there is a difference 
between patients with these specific CHEK2 variants in 
response to (chemo)therapy and survival is unknown yet, 
although a different response to chemotherapy of differ-
ent CHEK2 variants is suggested (Chrisanthar et al. 2008). 
This deserves further investigation which will require inter-
national collaboration as in the Netherlands mainly the 
CHEK2 1100delC mutation is prevalent.
Despite the unique results of the current paper, some 
limitations should be addressed. Patients included in the 
current study have been diagnosed and treated in different 
time periods, resulting in different treatment regimens used. 
In view of the small number of patients receiving a taxane 
as first-line chemotherapy for MBC, no conclusions can be 
drawn for this type of chemotherapy for CHEK2 1100delC 
MBC patients. A second limitation in the analyses regard-
ing the efficacy of chemotherapy is that in some patients, 
endocrine therapy was given as consolidation therapy after 
chemotherapy, potentially affecting PFS, but which is com-
mon practice in palliative care and outside of clinical tri-
als. The number of patients treated with consolidation 
Table 4  First-line endocrine therapy for metastatic breast cancer
a None of the added variables (age at diagnosis, ER status, adjuvant 
chemotherapy, metachronous contralateral breast cancer, type of first 
metastases, distant disease-free interval) had >10 % influence on the 
hazard ratio (HR); therefore, no multivariate HR was calculated
CHEK2 Non-CHEK2 P
N % N %
Number of patients 36 32
Type of endocrine therapy
 Tamoxifen 26 72 17 53 0.23
 Aromatase inhibitor 7 19 9 28
 Other 3 8 6 19
Best response
 Objective response 5 14 6 19 0.82
 Stable disease 18 52 14 45
 Progressive disease 12 34 11 36
 Unknown 1 – 1 –
Progression-free survival
 6 months 20 56 19 59 0.12
 12 months 14 39 13 41
 24 months 3 8 6 19
 HR univariatea 1.50 0.90–2.49
Overall survival
 6 months 36 100 31 97 0.12
 12 months 34 94 28 88
 24 months 26 78 26 81
 HR univariatea 1.51 0.89–2.57
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endocrine therapy, however, was comparable in the CHEK2 
(n = 18) and the non-CHEK2 groups (n = 19). Further-
more, we performed analyses for PFS, with censoring at 
date of start of consolidation endocrine therapy in respec-
tive patients, showing similar results.
DNA diagnostics for hereditary breast cancer is recently 
extended with the CHEK2 gene in the Netherlands and in 
the near future potentially also in other countries having 
a relatively high prevalence of CHEK2 mutations. In this 
view, results of the current study regarding the efficacy of 
systemic therapy in CHEK2 1100delC mutation carriers are 
very relevant and may helpful with respect to counseling 
and treatment of respective patients.
In conclusion, the presence of a CHEK2 1100delC 
mutation has currently no impact on the choice of type 
of systemic treatment in respective MBC patients, nei-
ther for chemotherapy nor for endocrine therapy, and our 
findings do not explain the previously reported worse sur-
vival regarding CHEK2 1100delC BC. Our observations 
are important for the counseling and treatment of CHEK2 
1100delC BC patients, as CHEK2 1100delC mutation test-
ing is currently being offered in the Netherlands to familial 
BC families. On the other hand, the data underscore that 
further investigations for CHEK2 1100delC-associated BC 
in greater sample sizes, and other specific CHEK2 muta-
tions, being more prevalent in other countries, are war-
ranted aiming at increased knowledge and further personal-
ized therapy.
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